📢KC-WISE Upper GI proffered #ESMO25 ➡️Met. HER2+ gastric/GEJ, previosly treated with trastuzumab ➡️Anbenitamab-ChT vs ChT ✅PFS: 7.1 vs. 2.7 months HR: 0.25; (0.17 to 0.39) P<0.0001 😮 ✅OS: 19.6 vs. 11.5 months HR: 0.29; (0.17 to 0.50) P<0.00001 😮 ✅ORR: 56% vs. 11%

Domvanalimab, zimberelimab, and FOLFOX in advanced GC/GEJC/EAC #ESMO25 #ESMOAmbassadors 👉 ORR: 59%, TAP>5% 69% 👉 mPFS: 12.9 mo 👉 mOS: 26.7% 🧐Promising efficacy for anti-TIGIT plus anti-PD1 @myesmo

RC118 (CLDN18.2-ADC) combined with PD-1 blockade or RC148 (PD-1/VEGF bispecific) for locally advanced la/m G/GEJA #ESMO25 #ESMOAmbassadors 👉ORR: 57 vs 33% , DCR: 95 vs 67% 👉mPFS: 7.9 vs 4.3 mo 🧐Interesting efficacy for the bispecific AB in combo with anti-CLDN18.2 @myesmo

📢 #ESMO25 | #NETs COMPETE trial: ¹⁷⁷Lu-edotreotide vs everolimus in G1–2 GEP-NETs 🧩 mPFS 23.9 vs 14.1 mo | HR 0.67 (95% CI 0.48–0.95); p=0.022 🧩 ORR 22% vs 4% (p<0.0001) ⚕️ Drug-related discontinuations: 2% vs 15% 💡 ¹⁷⁷Lu-edotreotide outperforms everolimus, safer ✅

The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line). Radioligand therapy superior to everolimus. #ESMO25 Jaume Capdevila

TRIPLET HCC ➡️atezo/bev + 1mg ipi vs atezo/bev ➡️no improvements in ORR /PFS/ OS ➡️higher toxicity despite 1mg ipi Need to mind the liver! #ESMO25 ILCA Jordi Bruix

PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: 82 (-) vs 58% (+) 🧐Very innovative trail design, ctDNA guided ACT is the future @myesmo

Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #PancreaticCancer #GeriOnc #CancerResearch #SuppOnc PanCAN Let's Win Pancreatic Cancer 💜

It used to take a decade to see so many changes in practice Now it takes one single conference day. #ESMO25 #ESMOAmbassadors

⭐️Intermediate stage HCC⭐️ ➡️how to integrate LRT/IO; do we need for all,what is tace eligible ➡️which LRT-immunogenicity evident ➡️patient factors imp ➡️curing select bclc b with effective tx ➡️endpoint considerations imp in trial design 🎉fabulous overview David James Pinato 🇺🇦 #esmo2025

Comprehensive overview of treatment sequencing in #HCC #ESMO2025👏🏻 ➡️how to choose IO options first-line ➡️TKI choices second-line, limited data and difficulties in accessing treatments ➡️importance of pt factors at MDT ➡️biomarkers still a huge unmet need Angela Lamarca

HRS-4642: KRAS G12D specific inh ➡️30 pts with first-line GnP ➡️ORR 63% ➡️87% >|=grade 3 AEs - most haem ‼️imp for trial design of combos ?sequencing ? Maintenance ➡️ctDNA role emerging ? Adaptive designs #esmo2025 #PDAC OncoAlert

Unfortunately another negative triplet #HCC ➡️ IMbrave152/SKYSCRAPER-14 Atezo/bev/ tiragolumab (anti-tigit) v.atezo/bev ➡️mPFS 8.3 vs 8.2; HR OS 0.94 ➡️more toxicity However in this triplet - little activity evident ; need understand tigit role #esmo2025 OncoAlert ILCA

Update of #Checkmate8HW first-line subgroup for PFS with early overall OS results from @sarah_lonardi1 @esmo #ESMO25 #cancer #cancerresearch Bristol Myers Squibb

Does chemotherapy affect the biology of BRAF V600E mCRC when combined with encorafenib + ceruximab? Answer appears to be YES! Very intriguing translational finding showing that addition of chemo to E+C reduces development of acquired RAS, MAP2K1 , and other mutations that drive

IKF-035/ABC-HCC phs IIIb: Atezolizumab + Bevacizumab vs TACE in intermediate-stage HCC #ESMO25 #ESMOAmbassadors 👉 TTFS: 14 vs vs 9 mo 🧐BCLC B is not any more the ”domain” of local therapies, but intent of treatment is more than ever key for MDT discussion @myesmo EASL Education

#ESMO25 turning 🧊 ➡️🔥? 🚨The phase 3 STELLAR-303 trial evaluated zanzalintinib + atezolizumab vs regorafenib in 901 patients with previously treated, non–MSI-H/dMMR mCRC. 💡 Zanzalintinib is a novel multitargeted TKI that inhibits TAM kinases (TYRO3, AXL, MER), MET, and VEGF

🔥data at #ESMO25 #ESMO2025 this morning from Sara Lonardi : ⭐️prelim OS 78% at 5 years with ipi/nivo in CM-8HW -Scott Kopetz : ⭐️Chemo +EC leads to fewer resistance mutations than EC alone and absolutely masterful discussion as usual by Sharlene Gill, MD, MPH, MBA, FASCO, including clues as to who may

Satellite lesions vs intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling HEPATOLOGY Journal doi.org/10.1097/HEP.00… 👉highly concordant mutational landscape of IM & SL 👉 poor long-term survival 🧐both should be categorized

What is the role of pre-op RT in esophagus/GEJ cancer post ESOPEC & now MATTERHORN? I think we all agree pre-op RT not needed for all, but here is my take on 5 settings should still consider. Key is patient selection, weighing risks of local vs. distant recurrence. OncoAlert